Mitochondrial Dysfunction Drives Aortic Aging and Degeneration
Background
The thoracic aorta, the body's largest artery, undergoes significant changes with age, becoming stiffer and less compliant. This age-related stiffening increases the risk of serious cardiovascular conditions such as aneurysmal disease, hypertension, and diastolic dysfunction. While mitochondrial dysfunction is a known contributor to various non-age-related aortopathies and is recognized as a fundamental hallmark of aging, the specific contribution of mitochondrial dysfunction to the natural process of aortic aging has remained less understood.
Results
The study revealed that elamipretide treatment significantly mitigated age-related mitochondrial decline. ELAM restored complex II-linked respiration in aged mice to levels comparable to those observed in young mice, indicating a reversal of age-associated mitochondrial respiratory chain impairment. Furthermore, elamipretide also improved relative phosphorylative flux, a measure of mitochondrial energy production efficiency. Beyond mitochondrial function, the treatment reduced inflammatory MMP9 (Matrix Metalloproteinase-9, an enzyme involved in tissue remodeling and inflammation) expression and decreased the number of elastin breaks in the aortas of aged mice. Bulk RNA sequencing analysis confirmed that elamipretide treatment profoundly affected the aortic transcriptome in an age-dependent manner, specifically reducing the expression of senescent and associated pro-inflammatory genes.
Why It Matters
This research provides compelling evidence that mitochondrial dysfunction is a primary driver of age-related aortic degeneration. The successful intervention with elamipretide highlights its potential as a therapeutic strategy. This finding suggests that targeting mitochondrial health could offer a novel approach to prevent or reverse age-related vascular stiffening and associated diseases. If validated in further studies, this could lead to clinical applications for improving cardiovascular health in aging populations. Future research should focus on dose-response studies and eventually progress to human clinical trials (e.g., Phase II) to confirm these promising results.